"Promising Drug Breakthrough for Colorectal and Other Cancers"

Researchers have developed a new radioactive substance called CB-2PA-NT, which targets neurotensin receptors found in various cancers, and shows high uptake and retention in tumors while maintaining a clear distinction from surrounding tissues. This substance holds promise for an innovative theranostics strategy, combining therapy and diagnostics, and could potentially advance personalized medicine for cancer patients. Human imaging studies using CB-2PA-NT are pending regulatory approval.